Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors

Journal of Immunotherapy

Volumn 29, Issue 2, 2006, Pages 151-164

  Stauffer, Jimmy K ^a   Khan, Tahira ^a   Salcedo, Rosalba ^b   Hixon, Julie A ^a   Lincoln, Erin ^b   Back, Timothy C ^b   Wigginton, Jon M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Angiogenesis; Apoptosis; Cytokine; Fluorescence; Metastasis

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ACTIN; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GREEN FLUORESCENT PROTEIN; RECOMBINANT INTERLEUKIN 12; RED FLUORESCENT PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE; FLUORESCENCE ANGIOGRAPHY; GROWTH INHIBITION; IMAGING SYSTEM; MALE; METASTASIS; MICROSCOPY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CYTOKINES; DEXTRANS; DIAGNOSTIC IMAGING; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENCE; GREEN FLUORESCENT PROTEINS; INDOLES; INTERLEUKIN-12; LUMINESCENT PROTEINS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA;

EID: 32144437228     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000190167.76663.c7     Document Type: Article

References (41)

1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott, Williams, & Wilkins; 2002:895-937.
2. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 2003;8:278-292.
3. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005;17:7-13.
4. Meitar D, Crawford SE, Rademaker AW, et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol. 1996;14:405-414.
5. Rossi AR, Pericle F, Rashleigh S, et al. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood. 1994;83:1323-1328.
6. Sarkar AK, Nuchtern JG. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res. 2000;60:1908-1913.
7. Metelitsa LS, Naidenko OV, Kant A, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001;167:3114-3122.
8. Lode HN, Xiang R, Duncan SR, et al. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA. 1999;96:8591-8596.
9. Turner JG, Rakhmilevich AL, Burdelya L, et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol. 2001;166:89-94.
10. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA. 2002;99:11399-11404.
11. Ribatti D, Ponzoni M. Antiangiogenic strategies in neuroblastoma. Cancer Treat Rev. 2005;31:27-34.
12. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol. 2000;18:4077-4085.
13. Pertl U, Wodrich H, Ruehlmann JM, et al. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood. 2003;101:649-654.
14. Redlinger RE Jr, Mailliard RB, Lotze MT, et al. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. J Pediatr Surg. 2003;38:301-307.
15. Neal ZC, Yang JC, Rakhmilevich AL, et al. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res. 2004;10:4839-4847.
16. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, et al. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2000;60:4315-4319.
17. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000;6:529-535.
18. Abel F, Sjoberg RM, Nilsson S, et al. Imbalance of the mitochondrial pro- and anti-apoptotic mediators in neuroblastoma tumours with unfavourable biology. Eur J Cancer. 2005;41:635-646.
19. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
20. Weiss WA, Aldape K, Mohapatra G, et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997;16:2985-2995.
21. Okabe M, Ikawa M, Kominami K, et al. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 1997;407:313-319.
22. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581-586.
23. Wigginton JM, Park JW, Gruys ME, et al. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol. 2001;166:1156-1168.
24. Wigginton JM, Gruys E, Geiselhart L, et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest. 2001;108:51-62.
25. Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann NY Acad Sci. 2004;1028:150-156.
26. Khosravi-Far R, Esposti MD. Death receptor signals to mitochondria. Cancer Biol Ther. 2004;3:1051-1057.
27. Li H, Zhu H, Xu CJ, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501.
28. Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome C release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481-490.
29. Wei MC, Lindsten T, Mootha VK, et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome C. Genes Dev. 2000;14:2060-2071.
30. Madesh M, Antonsson B, Srinivasula SM, et al. Rapid kinetics of tBid-induced cytochrome C and Smac/DIABLO release and mitochondrial depolarization. J Biol Chem. 2002;277:5651-5659.
31. Hoffman R. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol. 2002;3:546-556.
32. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002;2:266-276.
33. Paris S, Sesboue R. Metastasis models: the green fluorescent revolution? Carcinogenesis. 2004;25:2285-2292.
34. Katz MH, Takimoto S, Spivack D, et al. An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer. Clin Exp Metastasis. 2004;21:7-12.
35. Yang M, Jiang P, Yamamoto N, et al. Real-time whole-body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein. Prostate. 2005;62:374-379.
36. El Hilali N, Rubio N, Blanco J. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase. Clin Cancer Res. 2005;11:1253-1258.
37. Nogawa M, Yuasa T, Kimura S, et al. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett. 2005;217:243-253.
38. Borgstrom P, Bourdon MA, Hillan KJ, et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate. 1998;35:1-10.
39. Ozerdem U, Stallcup WB. Early contribution of pericytes to angiogenic sprouting and tube formation. Angiogenesis. 2003;6:241-249.
40. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell. 2003;112:481-490.
41. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626-629.